Search

MRI plays an important role in the evaluation of kidney allografts for vascular complications as well as parenchymal insults. Transplant renal artery stenosis, the most common vascular complication of kidney transplant, can be evaluated by MRA using gadolinium and nongadolinium contrast agents as well as by unenhanced MRA techniques. Parenchymal injury occurs through a variety of pathways, including graft rejection, acute tubular injury, BK polyomavirus infection, drug-induced interstitial nephritis, and pyelonephritis. Investigational MRI techniques have sought to differentiate among these causes of dysfunction as well as to assess the degree of interstitial fibrosis or tubular atrophy (IFTA)-the common end pathway for all of these processes-which is currently evaluated by invasively obtained core biopsies. Some of these MRI sequences have shown promise in not only assessing the cause of parenchymal injury but also assessing IFTA noninvasively. This review describes current clinically used MRI techniques and previews promising investigational MRI techniques for assessing complications of kidney grafts.

Objective To assess treatment outcomes in tuberculosis patients participating in support group meetings in five districts of Karnataka and Telangana states in southern India. Methods Tuberculosis patients from five selected districts who began treatment in 2019 were offered regular monthly support group meetings, with a focus on patients in urban slum areas with risk factors for adverse outcomes. We tracked the patients' participation in these meetings and extracted treatment outcomes from the Nikshay national tuberculosis database for the same patients in 2021. We compared treatment outcomes based on attendance of the support groups meetings. Findings Of 30 706 tuberculosis patients who started treatment in 2019, 3651 (11.9%) attended support groups meetings. Of patients who attended at least one support meeting, 94.1% (3426/3639) had successful treatment outcomes versus 88.2% (23 745/26 922) of patients who did not attend meetings (adjusted odds ratio, aOR: 2.44; 95% confidence interval, CI: 2.10-2.82). The odds of successful treatment outcomes were higher in meeting participants than non-participants for all variables examined including: age [greater than or equal to] 60 years (aOR: 3.19; 95% CI: 2.26-4.51); female sex (aOR: 3.33; 95% CI: 2.46-4.50); diabetes comorbidity (aOR: 3.03; 95% CI: 1.91-4.81); human immunodeficiency virus infection (aOR: 3.73; 95% CI: 1.76-7.93); tuberculosis retreatment (aOR: 1.69; 1.22-2.33); and drug- resistant tuberculosis (aOR: 1.93; 95% CI: 1.21-3.09). Conclusion Participation in support groups for tuberculosis patients was significantly associated with successful tuberculosis treatment outcomes, especially among high-risk groups. Expanding access to support groups could improve tuberculosis treatment outcomes at the population level. Objectif Evaluer les resultats des traitements contre la tuberculose chez les patients qui assistent aux reunions des groupes d'entraide dans cinq districts des Etats du Karnataka et du Telangana, en Inde du Sud. Methodes Dans les cinq districts selectionnes, des patients tuberculeux ayant entame un traitement en 2019 se sont vu proposer des reunions mensuelles organisees a intervalles reguliers. Ces reunions etaient principalement destinees aux patients vivant dans des bidonvilles urbains et presentant des facteurs augmentant le risque d'issue defavorable. Nous avons suivi leur participation aux reunions et avons extrait des informations therapeutiques de la base de donnees nationale Nikshay sur la tuberculose concernant les memes patients en 2021. Nous avons ensuite compare l'issue des traitements a la presence aux reunions des groupes d'entraide. Resultats Sur 30 706 patients tuberculeux ayant entame un traitement en 2019, 3651 (11,9%) ont rejoi nt des groupes d'entraide. Sur l'ensemble des patients ayant assiste a au moins une reunion, 94,1% (3426/3639) ont connu une issue favorable au traitement, contre 88,2% (23 745/26 922) chez les patients qui n'y ont pas assiste (odds ratio ajuste, ORA: 2,44; intervalle de confiance de 95%, IC: 2,10-2,82). Les probabilites de reussite du traitement etaient plus elevees chez les participants aux reunions que chez les non-participants pour toutes les variables examinees, y compris pour les [greater than or equal to] 60 ans (ORA: 3,19; IC de 95%: 2,26-4,51); les patients de sexe feminin (ORA: 3,33; IC de 95%: 2,46-4,50); celles et ceux presentant une comorbidite liee au diabete (ORA: 3,03; IC de 95%: 1,91-4,81); une infection au virus de l'immunodeficience humaine (ORA: 3,73; IC de 95%: 1,76-7,93); un retraitement contre la tuberculose (ORA: 1,69; 1,22-2,33); et enfin, une tuberculose pharmacoresistante (ORA: 1,93; IC de 95%: 1,21-3,09). Conclusion La participation des patients atteints de tuberculose aux groupes d'entraide allait de pair avec de meilleurs resultats de traitement, surtout au sein des categories a haut risque. Promouvoir l'acces a ces groupes d'entraide pourrait ameliorer l'issue des traitements contre la tuberculose a l'echelle de la population. Objetivo Evaluar los desenlaces del tratamiento en pacientes con tuberculosis que participan en reuniones de grupos de apoyo en cinco distritos de los estados de Karnataka y Telangana en el sur de la India. Metodos Se ofrecieron reuniones mensuales regulares de grupos de apoyo a los pacientes con tuberculosis de cinco distritos seleccionados que comenzaron el tratamiento en 2019, con un enfoque en los pacientes de los suburbios urbanos con factores de riesgo de desenlaces adversos. Se realizo un seguimiento de la participacion de los pacientes en estas reuniones y se extrajeron los desenlaces del tratamiento de la base de datos nacional de tuberculosis Nikshay para los mismos pacientes en 2021. Se compararon los desenlaces del tratamiento en funcion de la asistencia a las reuniones de los grupos de apoyo. Resultados De 30 706 pacientes con tuberculosis que iniciaron el tratamiento en 2019, 3651 (11,9 %) asistieron a reuniones de grupos de apoyo. De los pacientes que asistieron al menos a una reunion de apoyo, el 94,1 % (3426/3639) presentaron desenlaces exitosos del tratamiento frente al 88,2 % (23 745/26 922) de los pacientes que no asistieron a las reuniones (razon de posibilidades ajustada, RPA: 2,44; intervalo de confianza del 95 %, IC: 2,10-2,82). Las posibilidades de obtener un desenlace satisfactorio del tratamiento fueron mayores en los participantes en las reuniones que en los no participantes para todas las variables examinadas, incluyendo: edad [greater than or equal to] 60 anos (RPA: 3,19; IC del 95 %: 2,26-4,51); sexo femenino (RPA: 3,33; IC del 95 %: 2,46-4,50); comorbilidad por diabetes (RPA: 3,03; IC del 95 %: 1,91-4,81); infeccion por el virus de la inmunodeficiencia humana (RPA: 3,73; IC del 95 %: 1,76-7,93); retratamiento de la tuberculosis (RPA: 1,69; IC del 95 %: 1,22-2,33); y tuberculosis resistente (RPA: 1,93; IC del 95 %: 1,21-3,09). Conclusion La participacion en grupos de apoyo para pacientes con tuberculosis se asocio de manera significativa con el exito de los desenlaces del tratamiento de la tuberculosis, en especial entre los grupos de alto riesgo. Ampliar el acceso a los grupos de apoyo podria mejorar los desenlaces del tratamiento de la tuberculosis a nivel de la poblacion., Introduction Estimates indicate that India has the largest number of tuberculosis patients (26%) and tuberculosis-related deaths (36%) in the world. (1) India's success in tackling tuberculosis is critical to achieving [...]

Genomic variants of the hepatitis B virus (HBV) preS/S protein are well-known to occur. Typically, immunity is gained through recovered HBV infection or by immunization. Very rarely, there are certain mutations that may enable HBV escape from the immune detection. PreS/S mutants may present with unpredictable pathobiologic, clinical, and transmittable implications. Standard laboratory testing for genomic HBV variants is not routinely performed by reference guidelines. s-variant HBV management remains challenging. Herein is a case of s-variant chronic HBV infection in a 55-year-old man. Diagnosis and treatment are described.

In the middle of a pandemic, patients with cough and fever are thought to have SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). It should be remembered that in the desert southwest of the United States, we have an ongoing epidemic of coccidioidomycosis (CM). There are additionally many other respiratory illnesses that could be confused with CoV-2 or overlooked. This is a case report of CoV-2 engrafted on chronic cavitary pulmonary CM. In a time where the coronavirus pandemic is becoming rampant, we demonstrate the case of a coinfection with cavitary pulmonary CM. In this case, the importance of detection of the coronavirus and treatment of the coinfection is explored.

Few international studies have investigated factors affecting domiciliary non-invasive ventilation (D-NIV) compliance, and data from the UK are limited. We assessed compliance (defined as [greater than or equal to] 4 h/night for at least 70% of the time) in a retrospective UK population study, at three time points (0-1 month, 3-4 months and 11-12 months), for all patients commenced on D-NIV over a 5-year period. A total of 359 patients were included. Non-compliant vs. compliant patients were significantly younger (median age 64 (IQR 52-72) vs. 67 (58-75) years, p = 0.032) and more likely to have schizophrenia, consistent at both 3-4 months (5% vs. 1%, p = 0.033) and 11-12 months (5% vs. 2%, p = 0.049). Repeated measures ANOVA demonstrated that the minutes [median (IQR)] of D-NIV used significantly increased at the three time points (0-1 month, 3-4 months and 11-12 months) for patients with hypertension [310 (147.5-431) vs. 341 (89-450) vs. 378 (224.5-477.5), p = 0.003]; diabetes [296.5 (132.5-417.5) vs. 342.5 (94.5-438.5) vs. 382 (247.5-476.25), p = 0.002] and heart failure [293 (177-403) vs. 326 (123-398) vs. 365 (212-493), p = 0.04]. In conclusion, younger and comorbid schizophrenic patients have lower D-NIV compliance rates, and our data suggest that persistence with D-NIV over a year may improve overall use., Author(s): Amar J. Shah [sup.1] [sup.2], Katia Florman [sup.1], Nitika Kaushal [sup.1], Hiu Fung Kwong [sup.1], Akul Karoshi [sup.1], Laura White [sup.1], Ryan Walker [sup.1], Yan-Pin Lin [sup.1], Ho Juen [...]